18331004. NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY simplified abstract (Massachusetts Institute of Technology)
Contents
- 1 NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY
Organization Name
Massachusetts Institute of Technology
Inventor(s)
Michael Birnbaum of Arlington MA (US)
Brooke Huisman of Clarkston MI (US)
Chiara Romagnani of Berlin (DE)
[[:Category:Timo R�ckert of Berlin (DE)|Timo R�ckert of Berlin (DE)]][[Category:Timo R�ckert of Berlin (DE)]]
NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY - A simplified explanation of the abstract
This abstract first appeared for US patent application 18331004 titled 'NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY
Simplified Explanation
The patent application provides peptides that bind to HLA-E and modulate immune cell activity, selectively activating NKG2C+ cells and inhibiting NKG2A+ cells.
- Peptides bind to HLA-E
- Activate NKG2C+ immune cells
- Inhibit NKG2A+ cells
- Treat autoimmune diseases, infectious diseases, and cancer
Potential Applications
The technology can be applied in the following areas:
- Treatment of autoimmune diseases
- Treatment of infectious diseases
- Treatment of cancer
Problems Solved
The technology addresses the following issues:
- Overactive immune responses
- Lack of targeted immune cell activation
- Limited treatment options for certain diseases
Benefits
The technology offers the following benefits:
- Selective immune cell activation
- Potential for personalized medicine
- Improved treatment outcomes
Potential Commercial Applications
The technology can be utilized in various commercial applications, such as:
- Pharmaceutical industry
- Biotechnology companies
- Immunotherapy research
Possible Prior Art
Prior art may include:
- Peptide-based therapies targeting immune cells
- HLA-E binding peptides in immunotherapy research
Unanswered Questions
1. How specific are the peptides in targeting NKG2C+ and NKG2A+ cells? 2. What are the potential side effects of modulating immune cell activity with these peptides?
Original Abstract Submitted
Peptides capable of binding to HLA-E and affecting immune cell activity are provided. Such peptides can selectively activate NKG2C+ immune cells such as natural killer (NK) cells and/or can inhibit NKG2A+ cells to decrease or suppress immune cell responses. Methods of use of the peptides are also disclosed, for instance, for treating or inhibiting the development or progression of a multitude of illnesses and conditions, including autoimmune disease, infectious disease such as viral or bacterial infection, and proliferative disorders such as cancer.
